Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR1480307

GTEX

8d56044b-45b0-52e4-ae59-318b8f675bd5

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.433
  • APICAL_SURFACE+0.394
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.355
  • KRAS_SIGNALING_DN+0.331
  • KRAS_SIGNALING_UP+0.287
  • INTERFERON_ALPHA_RESPONSE+0.225
  • COAGULATION+0.216
  • INFLAMMATORY_RESPONSE+0.206
  • PANCREAS_BETA_CELLS+0.204
  • MYOGENESIS+0.202

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.576
  • MYC_TARGETS_V2-0.517
  • DNA_REPAIR-0.474
  • MYC_TARGETS_V1-0.464
  • UNFOLDED_PROTEIN_RESPONSE-0.456
  • MTORC1_SIGNALING-0.410
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.387
  • E2F_TARGETS-0.376
  • PI3K_AKT_MTOR_SIGNALING-0.310
  • G2M_CHECKPOINT-0.309

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1325964
brain-umap@2
GTEX—0.946
2SRR1320012
brain-umap@2
GTEX—0.921
3SRR659625
brain-umap@2
GTEX—0.919
4SRR1323536
brain-umap@2
GTEX—0.914
5SRR1456333
brain-umap@2
GTEX—0.910
6SRR1312743
brain-umap@2
GTEX—0.907
7SRR1368964
brain-umap@2
GTEX—0.907
8SRR1322768
brain-umap@2
GTEX—0.906
9SRR1321674
brain-umap@2
GTEX—0.906
10SRR1467212
brain-umap@2
GTEX—0.903

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.433Remibrutinib— uncovered
APICAL_SURFACE0.394Temsirolimus— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.355Inavolisib— uncovered
KRAS_SIGNALING_DN0.331Remibrutinib— uncovered
KRAS_SIGNALING_UP0.287Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.225Inavolisib— uncovered
COAGULATION0.216Binimetinib— uncovered
INFLAMMATORY_RESPONSE0.206Idelalisib— uncovered
PANCREAS_BETA_CELLS0.204Cobimetinib— uncovered
MYOGENESIS0.202Inavolisib— uncovered
TGF_BETA_SIGNALING0.177Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.174Idelalisib— uncovered
COMPLEMENT0.169Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.166Idelalisib— uncovered
ALLOGRAFT_REJECTION0.148Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.128Inavolisib— uncovered
APICAL_JUNCTION0.104Inavolisib— uncovered
BILE_ACID_METABOLISM0.104Inavolisib— uncovered
UV_RESPONSE_DN0.103Inavolisib— uncovered
SPERMATOGENESIS0.083Inavolisib— uncovered